Despite decades of sepsis research, no specific therapies for sepsis have emerged and current management still relies on source control, antibiotics, and organ support. With improved understanding of sepsis pathophysiology and the development of new techniques to enable better characterization of patients with sepsis, clinical trials are beginning to better target new interventions at those patients most likely to respond. This article discusses advances in sepsis therapeutics designed to improve endothelial cell function, purify the blood to help restore immune homeostasis, and provide immunostimulation for patients with immune exhaustion.
Keywords: Biomarkers; Immunosuppression; Interferon; Microcirculation; Organ dysfunction; Personalization; Septic shock; Thrombomodulin.
Copyright © 2017 Elsevier Inc. All rights reserved.